These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24747994)

  • 1. Diabetes, incretin hormones and cardioprotection.
    Myat A; Redwood SR; Gersh BJ; Yellon DM; Marber MS
    Heart; 2014 Oct; 100(19):1550-61. PubMed ID: 24747994
    [No Abstract]   [Full Text] [Related]  

  • 2. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure.
    Takahashi A; Ihara M; Yamazaki S; Asanuma H; Asakura M; Kitakaze M
    Int Heart J; 2015; 56(4):372-6. PubMed ID: 26104180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin-based therapies: facing the realities of benefits versus side effects.
    Lebovitz HE
    Diabetes Technol Ther; 2013 Nov; 15(11):909-13. PubMed ID: 24111860
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.
    Avogaro A; Vigili de Kreutzenberg S; Fadini GP
    Curr Diab Rep; 2014; 14(5):483. PubMed ID: 24676508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular biology of the incretin system.
    Ussher JR; Drucker DJ
    Endocr Rev; 2012 Apr; 33(2):187-215. PubMed ID: 22323472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating incretin-based therapy into type 2 diabetes management.
    Brunton SA
    J Fam Pract; 2013 Jun; 62(6 Suppl CME):S1-8. PubMed ID: 23828807
    [No Abstract]   [Full Text] [Related]  

  • 8. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond glycemic control: cardiovascular effects of incretin-based therapies.
    Angeli FS; Shannon RP
    Front Horm Res; 2014; 43():144-57. PubMed ID: 24943305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pleiotropic effects of incretins and antidiabetic drugs with incretine mechanism].
    Winkler G
    Orv Hetil; 2013 Feb; 154(7):248-55. PubMed ID: 23395788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system.
    Xiao C; Dash S; Lewis GF
    Cardiovasc Hematol Agents Med Chem; 2012 Dec; 10(4):289-94. PubMed ID: 22827289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.
    Eckerle Mize DL; Salehi M
    Curr Diab Rep; 2013 Jun; 13(3):307-18. PubMed ID: 23479200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretins and microRNAs: Interactions and physiological relevance.
    Radbakhsh S; Sathyapalan T; Banach M; Sahebkar A
    Pharmacol Res; 2020 Mar; 153():104662. PubMed ID: 31982487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-based practice use of incretin-based therapy in the natural history of diabetes.
    Schwartz S
    Postgrad Med; 2014 May; 126(3):66-84. PubMed ID: 24918793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 and diabetes 2012.
    Monami M; Di Pasquale G; Rowzee A; Rotella CM; Mannucci E
    Exp Diabetes Res; 2012; 2012():768760. PubMed ID: 23431286
    [No Abstract]   [Full Text] [Related]  

  • 20. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.